Unicycive Therapeutics, Inc.
UNCY
$4.44
-$0.31-6.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.40% | 46.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.84% | -13.74% | |||
| Operating Income | 12.84% | 13.74% | |||
| Income Before Tax | -1,231.05% | 102.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,231.05% | 102.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,231.05% | 102.65% | |||
| EBIT | 12.84% | 13.74% | |||
| EBITDA | 12.83% | 13.76% | |||
| EPS Basic | -1,299.31% | 102.15% | |||
| Normalized Basic EPS | -1,173.77% | 102.40% | |||
| EPS Diluted | -4.44% | 75.35% | |||
| Normalized Diluted EPS | -1,237.15% | 102.26% | |||
| Average Basic Shares Outstanding | 5.31% | 10.50% | |||
| Average Diluted Shares Outstanding | -0.66% | 17.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||